Drug intelligence / Profile preview

TBA402

Development stage: Preclinical
Lead developer: FibroGenesis
Modality: Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

TBA402 is an investigational exosome-based therapy being developed by FibroGenesis (a subsidiary of SpinalCyte) for the treatment of vascular diseases. The product consists of exosomes derived from human dermal fibroblasts (HDFs), which are engineered or selected to promote angiogenesis and facilitate vascular repair. As part of the FibroGenesis HDF platform, TBA402 aims to harness the paracrine signaling potential of fibroblast-secreted vesicles to restore blood flow and tissue perfusion. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on TBA402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBA402.

Explore the full profile